Sandbox:khurram: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 145: | Line 145: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |DIC | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Disseminated intravascular coagulation (DIC)<ref name="pmid25535423">{{cite journal |vauthors=Venugopal A |title=Disseminated intravascular coagulation |journal=Indian J Anaesth |volume=58 |issue=5 |pages=603–8 |date=September 2014 |pmid=25535423 |pmc=4260307 |doi=10.4103/0019-5049.144666 |url=}}</ref> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 156: | Line 156: | ||
| style="background: #F5F5F5; padding: 5px;" |Increased | | style="background: #F5F5F5; padding: 5px;" |Increased | ||
|Increased | |Increased | ||
| | |Shistocytes | ||
| style="background: #F5F5F5; padding: 5px;" |Increased | | style="background: #F5F5F5; padding: 5px;" |Increased | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 162: | Line 162: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Elevated fibrin degradation products | | style="background: #F5F5F5; padding: 5px;" | | ||
* | * Elevated fibrin degradation products (D-dimers) | ||
* Decreased fibrinogen | |||
* Decreased factor V and VIII | |||
|- | |- | ||
|Antiphospholipid antibody syndrome | |Antiphospholipid antibody syndrome |
Revision as of 18:51, 23 August 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||||
Symptoms of DVT | Symptoms of Pulmonary Embolism | Symptoms of Myocardial Infarction | Tenderness in extremities | Edema in extremities | Warmth in extremities | Skin necrosis | Platelet count | PT | aPTT | Peripheral blood smear | Bleeding time | Doppler ultrasound | Chest CT scan | Head CT with contrast | ||||
Antithrombin deficiency | - | - | - | - | - |
| ||||||||||||
Factor V Leiden mutation | ||||||||||||||||||
Protein C deficiency | ||||||||||||||||||
Protein S deficiency | ||||||||||||||||||
Prothrombin gene mutation | ||||||||||||||||||
Disseminated intravascular coagulation (DIC)[1] | Decreased | Increased | Increased | Shistocytes | Increased |
| ||||||||||||
Antiphospholipid antibody syndrome | ||||||||||||||||||
Heparin induced thrombocytopenia (HIT) |
References
- ↑ Venugopal A (September 2014). "Disseminated intravascular coagulation". Indian J Anaesth. 58 (5): 603–8. doi:10.4103/0019-5049.144666. PMC 4260307. PMID 25535423.